PURPOSE: A composition for treating central nervous system disease is provided to improve neurobehavioral disorders and cognitive dysfunctions to a level which is similar to the level of a normal animal by restoring neuronal cells in which oligodendrocyte progenitor cells are damaged, thereby being used as cell remedial agents for central nervous system disease. CONSTITUTION: A composition for treating central nervous system disease includes an oligodendrocyte progenitor cell as an active ingredient. The oligodendrocyte progenitor cell is a stem cell which is transformed with an expression vector including an Olig2 gene encoding nucleic acid molecule. The stem cell is a primary cultured stem cell or an immortalized stem cell in which the primary cultured stem cell is genetically transformed. The central nervous system disease is one selected from cerebral palsy (periventicular leukomalacia), multiple sclerosis, spinal cord injury, Lou Gehrig disease or cerebral trauma.본 발명은 희돌기교전구세포의 중추신경계 질환의 세포 치료제로서의 용도에 관한 것이다. 본 발명의 희돌기교전구세포를 소아뇌성마비 및 다발성축삭경화증과 같은 중추신경계 질환 동물 모델의 뇌에 주입하는 경우 손상된 뇌 신경세포를 복구하며 신경행동장애와 인지기능장애를 정상 동물의 수준과 유사한 수준까지 개선하는 활성을 갖는다. 따라서, 본 발명의 희돌기교전구세포는 중추신경계질환의 세포 치료제로 사용될 수 있다.
